FGFR3

ENSG00000068078

Target class

Kinase

Chromosome

Approved drugs

Clinical candidates (approved and in development)

Approved drugs: 7

ClinGen gene-disease validity: Definitive

Clinical candidates (approved and in development): 24

Chemical probe available: Yes

Target name: FGFR3

Gene name: Fibroblast growth factor receptor 3

Gene symbol: FGFR3

Previous gene symbols

Protein name: Fibroblast growth factor receptor 3 (FGFR-3) (EC 2.7.10.1) (CD antigen CD333)

CEK2
JTK4
CD333

Gene biotype: Protein coding

Gene family: Receptor tyrosine kinases|CD molecules|I-set domain containing

Target class: Kinase

Target type: Human gene

Tissues expressed in: 49

Protein localisation evidence grade: Supported

Highest tissue expression: 364.55

Tissue specificity (Gini): 0.708

Tissue specificity (tau): 0.893

KEGG gene identifiers

hsa:2261

Protein interaction confidence: 0.854135

Protein interaction partners: 89

R-HSA-1839130
R-HSA-2033515
R-HSA-5655332
R-HSA-8853334

End position: 1808873

Start position: 1793286

Chromosome: 4

Strand: Forward

Ensembl gene ID: ENSG00000068078

HGNC ID: HGNC:3690
www.genenames.org

NCBI Gene ID: 2261

UniProt ID: P22607

[Isoform 1]: Cell membrane
Single-pass type I membrane protein. Cytoplasmic vesicle. Endoplasmic reticulum. Note=The activated receptor is rapidly internalized and degraded. Detected in intracellular vesicles after internalization of the autophosphorylated receptor.
SUBCELLULAR LOCATION: [Isoform 2]: Cell membrane
Single-pass type I membrane protein .
SUBCELLULAR LOCATION: [Isoform 3]: Secreted.
SUBCELLULAR LOCATION: [Isoform 4]: Cell membrane
Single-pass type I membrane protein .
Endoplasmic reticulum

Tissue specificity (tau): 0.892542
Expression inequality (Gini): 0.708225

Expression in transcripts per million

Skin - Not Sun Exposed (Suprapubic): 364.55
Skin - Sun Exposed (Lower leg): 356.5
Esophagus - Mucosa: 199.7
Brain - Caudate (basal ganglia): 148.39
Brain - Nucleus accumbens (basal ganglia): 135.37

Expression in transcripts per million

Skin - Not Sun Exposed (Suprapubic)364.55
Skin - Sun Exposed (Lower leg)356.5
Esophagus - Mucosa199.7
Brain - Caudate (basal ganglia)148.39
Brain - Nucleus accumbens (basal ganglia)135.37
Vagina112.34
Brain - Cortex109.62
Brain - Anterior cingulate cortex (BA24)104.69
Brain - Putamen (basal ganglia)101.3
Brain - Amygdala94.9
Brain - Frontal Cortex (BA9)81.13
Brain - Substantia nigra64.32
Brain - Cerebellum62.43
Brain - Hypothalamus53.88
Pancreas49.25
Brain - Hippocampus47.91
Testis39.93
Kidney - Medulla34.57
Brain - Cerebellar Hemisphere31.68
Brain - Spinal cord (cervical c-1)27.03
Liver25.5
Pituitary23.81
Kidney - Cortex23.23
Colon - Transverse17.17
Prostate15.63

And 29 more, listed on the interactive page.

GO:0000165
www.ebi.ac.uk
GO:0001501
www.ebi.ac.uk
GO:0001958
www.ebi.ac.uk
GO:0002062
www.ebi.ac.uk
GO:0003416
www.ebi.ac.uk
GO:0007259
www.ebi.ac.uk
GO:0008284
www.ebi.ac.uk
GO:0008543
www.ebi.ac.uk
GO:0010518
www.ebi.ac.uk
GO:0035988
www.ebi.ac.uk
GO:0042531
www.ebi.ac.uk
GO:0043410
www.ebi.ac.uk
GO:0051897
www.ebi.ac.uk
GO:0060349
www.ebi.ac.uk
GO:0070374
www.ebi.ac.uk
GO:1902178
www.ebi.ac.uk

GO:0005783
www.ebi.ac.uk
GO:0005794
www.ebi.ac.uk
GO:0005886
www.ebi.ac.uk
GO:0005925
www.ebi.ac.uk
GO:0030133
www.ebi.ac.uk

GO:0004713
www.ebi.ac.uk
GO:0005007
www.ebi.ac.uk
GO:0005515
www.ebi.ac.uk
GO:0017134
www.ebi.ac.uk
GO:0042802
www.ebi.ac.uk

regulation of catalytic activity
Studies
biochemical: NVS_ENZ_hFGFR3, is one of one assay component(s) measured or calculated from the NVS_ENZ_hFGFR3 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.
Biological samples
- cell-free
Evidence source
www.epa.gov

Related records

Trials (761)

[18F]Fluciclatide-PET, Pazopanib and Paclitaxel in Ovarian Cancer
12 Week Patient Study in Neovascular Age-related Macular Degeneration (AMD)
1st-line Activity of Dovitinib and Correlation With Genetic Changes in RCC
A BIOmarker Driven Trial With Nivolumab and Ipilimumab or VEGFR tKi in Naïve Metastatic Kidney Cancer
A Combination of Pazopanib and Carboplatin in Advanced Solid Malignancies
A Dose Escalation Study in Adult Patients With Advanced Solid Malignancies
A Dose Escalation Study of BIBF 1120 Together With Paclitaxel and Carboplatin in Patients With Advanced Stage Non-small-cell Lung Cancer
A Dose Escalation Study to Assess the Safety and Tolerability of HMPL-453 in Patients With Advanced Solid Malignancies
A Dose-escalation Study of BIBF 1120 in Japanese Patients With Advanced Solid Tumours
A Dose-Escalation Study of ENMD-2076 Administered Orally to Patients With Advanced Cancer
A Double-blind, Placebo-controlled, Randomized, Parallel-group Study to Evaluate the Activity of Oral AB1010 in Adults Patients With Moderate to Severe Chronic Plaque Psoriasis
A Drug-Drug Interaction Study of ENV-101 (Taladegib) on Nintedanib Pharmacokinetics in Healthy Subjects
A Follow-up Study Investigating Long Term Treatment With Nintedanib in Patients With Progressive Fibrosing Interstitial Lung Disease (PF-ILD)
A Modular Multi-Basket Trial to Improve Personalized Medicine in Cancer Patients (Basket of Baskets)
A Multi-center, Open-label Study of Oral ENMD-2076 for the Treatment of Patients With Advanced Fibrolamellar Carcinoma
A Multi-centre 3-arm Randomised Phase II Trial of BIBF 1120 Versus BIBW 2992 Versus Sequential Administration of BIBF 1120 and BIBW 2992 in Patients With Hormone-resistant Prostate Cancer
A Phase 1 Study of MKC-1 in Patients With Refractory Hematologic Malignancies
A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors
A Phase 1B Dose-escalation and Phase 2a Study of Carotuximab (TRC105) in Combination With Pazopanib in Patients With Advanced Soft Tissue Sarcoma
A Phase 1b/2 Clinical Study to Evaluate the Safety and Tolerability and Efficacy of AZD4547

Drugs (26)

Brivanib Fibroblast growth factor receptor inhibitor
Brivanib alaninate Fibroblast growth factor receptor inhibitor
CP-459632 Fibroblast growth factor receptor inhibitor
Derazantinib Fibroblast growth factor receptor inhibitor
Dovitinib Fibroblast growth factor receptor 3 inhibitor
E-7090 Fibroblast growth factor receptor 3 inhibitor
ENMD-2076 Fibroblast growth factor receptor 3 inhibitor
ENMD-981693 Fibroblast growth factor receptor inhibitor
Erdafitinib Fibroblast growth factor receptor inhibitor
Fexagratinib Fibroblast growth factor receptor inhibitor
Fgfr inhibitor debio 1347 Fibroblast growth factor receptor 3 inhibitor
Futibatinib Fibroblast growth factor receptor inhibitor
HMPL-453 Fibroblast growth factor receptor 3 inhibitor
Infigratinib Fibroblast growth factor receptor inhibitor
Infigratinib phosphate Fibroblast growth factor receptor inhibitor
LY-2874455 Fibroblast growth factor receptor inhibitor
Masitinib Fibroblast growth factor receptor 3 inhibitor
Nintedanib Fibroblast growth factor receptor inhibitor
Nintedanib esylate Fibroblast growth factor receptor inhibitor
Orantinib Fibroblast growth factor receptor inhibitor

FGFR3

Clinical evidence

Druggability

Names

Other names (3)

Classification

Expression and localisation

Pathways and interactions

Reactome pathways (4)

Genomic location

Identifiers

Cellular location

Tissue expression

Highest expression

All tissues (54)

Biological functions

Biological processes (16)

Cellular components (5)

Molecular functions (5)

Off-target safety

Studies

Biological samples

Related records

Trials (761)

Drugs (26)